| Dosage Form: | Infusion |
|---|---|
| Transport Package: | Carton |
| Specification: | 100ml |
| Trademark: | Sinolead |
| Origin: | China |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Generic Name | Ciprofloxacin Lactate and Sodium Chloride Injection 100ml |
| Strength | 100ml |
| Packing | 1bottle/box |
| Origin | China |
For simple and complex infections caused by ciprofloxacin-sensitive pathogens. When intravenous administration is beneficial to the patient:
Urinary tract infections - mild, moderate, severe and concurrent infections, applicable to the following pathogens: Escherichia coli (including secondary bacteremia), Klebsiella pneumoniae subspecies pneumonia, Enterobacter clovis, Serratia marcescens, Proteus mirabilis, Pluffetenella reggii. Morgan Bacillus, citrobacter Divos, citrobacter Fraudiensis, Pseudomonas aeruginosa, Staphylococcus epidermidis or Enterobacter faecalis.
Lower respiratory tract infection - Mild to moderate infection for the following causes: E. coli, Klebsiella pneumoniae subspecies pneumonia, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae and Haemophilus parainfluenza, and Streptococcus pneumoniae.
Skin and soft tissue infections - Mild to moderate infections for the following causes: Escherichia coli, Klebsiella pneumoniae subspecies pneumonia, Enterobacter cloacae, Proteus Mirabilis, Proteus vulgaris, Pruffeella stuartii, Bacillus morgana, Citrobacter Fredii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pyogenes.
Bone and joint infections - mild to moderate infections, suitable for infections caused by Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa.
If the infection may be caused by anaerobic bacteria, appropriate treatment should be taken.
In order to isolate and identify the bacteria causing the infection and determine their sensitivity to Siproxacin ®, appropriate bacterial cultures and susceptibility tests should be performed. The results of these trials may be treated with Siproxacin ® by intravenous drip until the results are reported, and the most appropriate treatment should be used once the results are clear.
Similar to other drugs, some strains of P. aeruginosa can rapidly develop resistance when treated with Siproxacin ®, so regular bacterial culture and susceptibility testing during treatment can not only understand the antibacterial effect, but also obtain information about the potential for resistance.
Inhalation anthrax in adults and children (post-exposure) : Reduces the incidence of disease after inhalation of atomized anthrax bacilli and delays disease progression.
The recommended dose for adults with mild to moderate urinary tract infections is 200mg every 12 hours, and 400mg every 12 hours for severe or concurrent infections.
400mg every 12 hours is recommended for mild and moderate lower respiratory tract infections, skin and soft tissue infections, and bone and joint infections.
Department of pediatrics
For the treatment of inhaled anthrax, the results of the risk-benefit assessment indicate that ciprofloxacin is appropriate for pediatric patients. For specific pediatric dose information see inhaled anthrax under Pharmacological Actions - Additional notes.
Cytochrome P450:
Ciprofloxacin is a known moderate inhibitor of the enzyme CYP450 1A2. Care should be taken in combination with other drugs metabolized through the same enzymatic pathway (e.g., theophylline, methylxanthine, caffeine, duloxetine, chlorazepine). Because ciprofloxacin inhibits metabolic clearance of these drugs, adverse drug reactions associated with elevated blood concentrations of these drugs may occur
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}